Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flu-C
- Development stage
- Unknown
- Lead developer
- Rameda Pharmaceutical Company
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flu-C is an over-the-counter (OTC) fixed-dose combination product developed and manufactured by Rameda (Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda) for the symptomatic relief of the common cold and influenza. Administered orally as sachets or capsules, Flu-C contains four active ingredients: paracetamol (acetaminophen), ascorbic acid (vitamin C), caffeine, and chlorphenamine maleate. Paracetamol provides analgesic and antipyretic effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2) in the central nervous system. Chlorphenamine maleate is a first-generation antihistamine that blocks histamine H1 receptors, reducing symptoms like runny nose, sneezing, and watery eyes. Caffeine acts as a central nervous system stimulant by antagonizing adenosine receptors, which helps counteract the sedative effects of chlorphenamine and enhances the analgesic efficacy of paracetamol. Ascorbic acid is included to support immune function and provide antioxidant defense during viral infections.
- Brand names
- Flu-C
- Other names
- ascorbic acid + caffeine + chlorphenamine + paracetamolascorbic acid + caffeine + chlorpheniramine + paracetamol
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Flu-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flu-C.